Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Strimvelis Market Expansion Outlook: What Revenue Opportunities Lie Ahead?
The expansion observed during the historical period was driven by progress in stem cell modification methods, the initial achievements of ada-scid gene therapy trials, growing regulatory backing for orphan drugs, heightened awareness of rare immunodeficiency conditions, and the creation of centralized treatment facilities.
The anticipated expansion during the forecast period is driven by the scaling up of gene therapy commercialization, heightened funding dedicated to rare disease pipelines, greater embrace of personalized medicine strategies, progress in vector engineering techniques, and improved worldwide availability of cutting-edge gene therapies. Key developments shaping this period include the growing preference for ex vivo gene therapy methods, a stronger emphasis on customized genetic interventions, expanded use of autologous stem cell systems, the broadening of gene therapy initiatives for rare conditions, and an increased focus on achieving durable immune recovery over the long term.
Download A Free Sample Report For Comprehensive Market Insights:
Strimvelis Market Demand Drivers Creating New Revenue Opportunities
The rise in rare genetic disorders is anticipated to drive the strimvelis market forward in the coming years. Rare genetic disorders are conditions resulting from DNA mutations or alterations, occurring infrequently in the broader population. The growing incidence of these disorders is linked to improvements in genetic testing that enable more accurate detection, as well as environmental factors and, occasionally, lifestyle choices that promote DNA mutations. Strimvelis is a gene therapy designed to treat rare genetic conditions, most notably adenosine deaminase severe combined immunodeficiency (ADA-SCID), by employing the patient’s own modified stem cells to insert a functional version of the ADA gene, thereby restoring immune system function and potentially providing a lasting cure for individuals suffering from this rare, life-threatening illness. For example, in May 2024, the National Health Service, a government entity in the United Kingdom, reported that approximately 17,000 individuals in England are affected by sickle cell disease—an inherited blood disorder—with around 250 new cases diagnosed annually. Consequently, the increasing prevalence of rare genetic disorders is fueling growth in the strimvelis market.
The upward trend in healthcare expenditure is projected to boost the strimvelis market’s expansion going ahead. Healthcare spending encompasses the total financial resources devoted to healthcare products and services over a given period, typically measured each year. This growth in expenditure is driven by factors such as an aging population, a higher incidence of chronic illnesses, progress in medical technology, climbing pharmaceutical costs, and broader access to healthcare services. Such spending plays a critical role in supporting therapies like strimvelis by supplying the financial backing needed for research, development, accessibility, and delivery of innovative treatments, enabling patients with rare diseases to obtain life-saving care. For instance, in April 2025, the American Medical Association, a US-based professional medical organization, stated that health spending in the United States rose by 7.5 percent in 2023, reaching 4.9 trillion dollars, or 14,570 dollars per person, a significant increase compared to the 4.6 percent growth observed in 2022. Hence, the escalation in healthcare expenditure is propelling the strimvelis market forward.
The increasing embrace of personalized medicine is expected to drive growth in the strimvelis market moving forward. Personalized medicine is a healthcare approach that customizes treatment and medical strategies to align with the distinct attributes of each patient. The expanding adoption of this approach stems from greater availability of precise diagnostic instruments, a movement toward value-oriented healthcare, and a growing need for more effective, customized treatment options that enhance patient outcomes. Strimvelis contributes to personalized medicine by offering a focused gene therapy designed specifically for individuals with adenosine deaminase severe combined immunodeficiency (ADA-SCID), using their own stem cells to deliver a functioning ADA gene, thus providing a tailored and potentially curative therapy based on the patient’s unique genetic makeup. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, noted that the FDA approved 16 new personalized treatments for rare disease patients in 2023, up from six in 2022. These newly approved treatments also included seven cancer drugs and three for other medical conditions. As a result, the growing trend toward personalized medicine is fueling the strimvelis market’s growth.
Strimvelis Market Segmentation: How Is The Market Structured Across Key Categories?
The strimvelis market covered in this report is segmented –
1) By Clinical Indication: Primary Indication, Patient Population, Clinical Study Data, Mechanism Of Action
2) By Distribution Channel: Hospitals, Pharmacies
3) By End User: Pediatric, Adult
Strimvelis Market Competitive Landscape And Leading Companies
Major companies operating in the strimvelis market are Orchard Therapeutics plc
Access The Complete Strimvelis Market Report:
Strimvelis Market Geographic Analysis: Where Is Demand Growing The Fastest?
North America was the largest region in the strimvelis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the strimvelis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model